Submission Details
| 510(k) Number | K160064 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | January 13, 2016 |
| Decision Date | March 11, 2016 |
| Days to Decision | 58 days |
| Submission Type | Abbreviated |
| Review Panel | Cardiovascular (CV) |
| Summary | Summary PDF |
K160064 is an FDA 510(k) clearance for the MoMe Kardia Wireless Ambulatory ECG Monitoring and Detection System, a Outpatient Cardiac Telemetry (Class II — Special Controls, product code QYX), submitted by Infobionic, Inc. (Lowell, US). The FDA issued a Cleared decision on March 11, 2016, 58 days after receiving the submission on January 13, 2016. This device falls under the Cardiovascular review panel. Regulated under 21 CFR 870.1025.
| 510(k) Number | K160064 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | January 13, 2016 |
| Decision Date | March 11, 2016 |
| Days to Decision | 58 days |
| Submission Type | Abbreviated |
| Review Panel | Cardiovascular (CV) |
| Summary | Summary PDF |
| Product Code | QYX — Outpatient Cardiac Telemetry |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 870.1025 |
| Definition | Devices Are Intended To Continuously Record And Analyze Electrocardiograms For Automatic Detection And Recording Of Cardiac Electrical Activity In An Outpatient Setting. Detected, Notifiable Events Are Transmitted To The Prescribing Clinician During The Monitoring Period By A 24/7 Attended Analysis Center After Review By A Qualified Individual. Devices May Allow Remote Access And Display Of Electrocardiograms Acquired. Not For Use For Detection Or Notification Of Hemodynamically Unstable Or Life-threatening Arrhythmias Or Cardiac Events Requiring Urgent Medical Response. Not Intended For Patients At Elevated Risk Of Serious Cardiovascular Events That Would Require Prompt Intervention. It Is Not Intended For Monitoring Patients During Cardiac Rehabilitation Outside Of Healthcare Facilities. Devices Are Intended For Prescription Use Only. |